DBV restructuring claims 200 jobs as it beats out a path toward peanut patch OK

DBV restructuring claims 200 jobs as it beats out a path toward peanut patch OK

Source: 
Endpoints
snippet: 

Regulatory troubles around its peanut allergy treatment have hurt DBV Technologies bad.

It became even clearer Thursday morning as the French biotech disclosed the scope of a global restructuring it announced back in June. More than 200 jobs are being cut, leaving a team of 90 to carry on with the hard task of scoring approval for its Viaskin Peanut patch.